Thu, Jul 24, 2014, 12:28 AM EDT - U.S. Markets open in 9 hrs 2 mins

Recent

% | $
Click the to save as a favorite.

Incyte Corporation Message Board

  • augie9876 augie9876 Mar 19, 2013 4:21 PM Flag

    Sorry

    To say, I think this still has a long way to fall. May go to 16 again. For those of you, who think it is a non event, think again. Tell it to the poor family who just lost a love one because INCY’s drug. Need to find out exactly what happened and why.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Do we know that he has died?

      First symptoms of PML don't appear for several months after the virus becomes active; at worst, Jakafi may have accelerated progress of already-active PML (even that is less likely than simple coincidence, based on existing evidence). We know that the patient had several blood draws before he went on Jakafi; if he was managed according to label instructions, there should be at least 2 between first treatment and appearance of PML symptoms; there may be evidence in retained samples (history of changes in levels of antibodies against the relevant virus [abbreviated JCV--I'll bet we use the abbreviation many more times].)

      I expect that JCV carriers among recipients of Jakafi will quickly be identified, and their serologic histories will be followed (This could cost $several MM, so it is a material event in itself). While the adverse event WILL be on the label forever, it shouldn't take more than a quarter to get a "beyond reasonable doubt" judgment of what part the drug may have played.

      Incidentally, the 8K says that Incyte was informed "last week." If the patient had been resident in the US I'd be screaming about that. But he was taking "Jakafi" (US drug) while resident in the UK, which may plausibly have slowed communication. I still expect clarification.

      One more thing: the patient was described a being leucopenic at the time Jakafi was initiated. In the natural history of MF, that puts him in the severity range where Incyte is trying to discourage initiation of Jakafi. There would be little objection from the company to a precautionary warning against starting leucopenic patients on Jakafi.

    • You sound like NObama! NO drug is 100%, that's just a fact. There is NO sure evidence INCY's drug was to blame. Stop the #$%$!

      • 1 Reply to traderal23
      • Not BS, Fact, need to find out what happened and why, If it was your family you would want to know. No reason for you to get hostile, this is what happens to Bio stocks when their drugs show a negative effect on a patient. They go down and in this case probably to 16.
        In this case someone lost their life and until all the facts come out INCI will suffer
        No reason for you to get hostile, this is what happens to Bio stocks when their drugs show a negative effect on a patient. They go down and in this case probably to 16.
        In this case someone lost their life and until all the facts come out INCI will suffer
        No reason for you to get hostile, this is what happens to Bio stocks when their drugs show a negative effect on a patient. They go down and in this case probably to 16.
        In this case someone lost their life and until all the facts come out INCI will suffer

 
INCY
48.98+1.06(+2.21%)Jul 23 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.